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Abstract
Drosophila melanogaster Held Out Wings (HOW) is a conserved RNA–binding protein (RBP) belonging to the STAR family,
whose closest mammalian ortholog Quaking (QKI) has been implicated in embryonic development and nervous system
myelination. The HOW RBP modulates a variety of developmental processes by controlling mRNA levels and the splicing
profile of multiple key regulatory genes; however, mechanisms regulating its activity in tissues have yet to be elucidated.
Here, we link receptor tyrosine kinase (RTK) signaling to the regulation of QKI subfamily of STAR proteins, by showing that
HOW undergoes phosphorylation by MAPK/ERK. Importantly, we show that this modification facilitates HOW dimerization
and potentiates its ability to bind RNA and regulate its levels. Employing an antibody that specifically recognizes
phosphorylated HOW, we show that HOW is phosphorylated in embryonic muscles and heart cardioblasts in vivo, thus
documenting for the first time Serine/Threonine (Ser/Thr) phosphorylation of a STAR protein in the context of an intact
organism. We also identify the sallimus/D-titin (sls) gene as a novel muscle target of HOW–mediated negative regulation and
further show that this regulation is phosphorylation-dependent, underscoring the physiological relevance of this
modification. Importantly, we demonstrate that HOW Thr phosphorylation is reduced following muscle-specific knock down
of Drosophila MAPK rolled and that, correspondingly, Sls is elevated in these muscles, similarly to the HOW RNAi effect.
Taken together, our results provide a coherent mechanism of differential HOW activation; MAPK/ERK-dependent
phosphorylation of HOW promotes the formation of HOW dimers and thus enhances its activity in controlling mRNA levels
of key muscle-specific genes. Hence, our findings bridge between MAPK/ERK signaling and RNA regulation in developing
muscles.
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Introduction
Regulation of gene expression at the level of RNA is often
mediated through the activities of RNA-binding proteins (RBPs),
which control different aspects of RNA metabolism of target genes
[1,2]. Drosophila melanogaster Held Out Wings (HOW) is an RBP
that belongs to a family of evolutionarily conserved ‘‘Signal
Transduction and Activation of RNA’’ (STAR) proteins [3].
STAR family members control a wide range of tissue differenti-
ation processes. For example, in mammals, Sam68 controls
spermatogenesis [4], and Quaking (QKI) regulates myelination
by Schwann cells and oligodendrocytes [5,6,7] as well as muscle
fiber maturation in Zebrafish [8]. In C. elegans, the STAR protein
GLD-1 promotes germ cell differentiation [9], while ASD-2 is
required for alternative splicing [10].
HOW, the Drosophila protein orthologous to mammalian QKI,
is highly expressed in muscles, tendons [11,12,13,14] and glial cells
[15,16], where it plays an essential role during development by
controlling the mRNA levels of an array of target genes [17].
HOW performs various activities on its target RNAs: it facilitates
the alternative splicing of stripe A, a transcription factor essential for
tendon cell maturation [18], and mediates specific splicing of the
septate junction constituent, nrxIV, thereby controlling glial cell
maturation [15]. It also functions by reducing mRNA levels of
various targets. For example, during gastrulation, HOW-depen-
dent downregulation of cdc25/string, a cell cycle promoting
phosphatase, is essential to inhibit cell division in invaginating
mesodermal cells [19].
Structurally, HOW contains a single maxi-KH RNA binding
motif that is flanked by two additional conserved domains, QUA1
and QUA2 [14]. While the QUA2 motif, located C terminally to
the KH domain, takes part in RNA-binding and contributes to the
specificity of RNA recognition [20,21,22], the QUA1 motif,
located N terminally to the KH domain, was shown to mediate
protein dimerization in GLD-1, Sam68 and QKI [23,24,25].
Notably, despite the fact that this domain is not essential for RNA-
binding, its deletion in GLD-1 nevertheless reduces the affinity of
the protein to the RNA binding motif TGE (Tra-2 and GLI
response element), by about ten-fold [26], suggesting that
dimerization of STAR proteins might enhance their affinity to
PLoS Genetics | www.plosgenetics.org 1 March 2012 | Volume 8 | Issue 3 | e1002632RNA. To date, it is not clear what regulates the degree of STAR
protein dimer formation.
Consistent with their expression in a wide range of tissues
during development, the activity of STAR proteins is highly
regulated at distinct post-translational levels, including phosphor-
ylation by various kinases (reviewed in [27]). These modifications
likely impinge on the activity, subcellular distribution, or the
formation of protein complexes of specific STAR proteins.
Phosphorylation of STAR proteins could couple regulation of
RNA metabolism with distinct signaling cascades operating in a
spatial and temporal restricted manner.
While Tyrosine phosphorylation of the C terminal regions of
both Sam68 [28] and QKI [29] has been established, Serine/
Threonine (Ser/Thr) phosphorylation has yet to be demonstrated
with respect to the QKI-subfamily of proteins. A more
evolutionarily distant STAR protein,Sam68, was shown to be
Ser/Thr phosphorylated, both by Cdc2 [30] and by ERK1/2 in
various culture lines, promoting differential activities. Specifically,
Sam68 phosphorylation by ERK1/2 in a lymphoma cell line
enhances its ability to regulate alternative splicing [31], while in
mouse spermatocytes and in HEK293 cells it induces cytoplasmic
accumulation correlated with its association with polyribosomes
[4,32]. We therefore postulated that ERK-dependent phosphor-
ylation of STAR proteins might affect their activity in a tissue-
specific manner.
In the present manuscript, we show that the Drosophila STAR
protein HOW is phosphorylated on conserved Thr residues.
Importantly, we demonstrate that in embryos in vivo, a particular
HOW isoform is phosphorylated on Thr, in a tissue-specific
manner. Moreover, we identify the major Z-disc gene product
sallimus (kettin/D-titin, sls [33,34]) as a specific target for HOW in
muscle cells and show that sls regulation is dependent on MAPK
phosphorylation of HOW. Mechanistically, we demonstrate that
HOW phosphorylation is essential for its efficient homodimeriza-
tion and RNA binding capability. Taken together, our results
reveal a molecular mechanism linking muscle-specific MAPK-
dependent phosphorylation of HOW to its ability to homodimer-
ize, bind its targets and regulate them, and thereby contribute to
muscle sarcomerization.
Results
HOW contains conserved consensus sites for MAPK/ERK
phosphorylation
Examination of HOW revealed two putative MAPK/ERK
consensus sites, comprised of Thr followed by Proline (Pro) (TP) at
residues 59 and 64 (Figure 1A). These could also serve as putative
sites for other Ser/Thr kinases such as Cyclin Dependent Kinases
(CDKs). Importantly, T64 is conserved throughout HOW(L)
sequences in all annotated Drosophila species, while T59 is found
only in closely related species (Figure 1B).
In addition to these conserved phosphorylation sites, HOW also
contains putative MAPK docking sites. These ‘‘D’’ [35] or ‘‘DEF’’
[36] domains frequently mediate high-affinity interactions between
MAPK and its substrates, allowing efficient phosphorylation of the
substrate [37]. HOW harbors three such potential D-domain
motifs,
85RKQLAA,
121KKEPLTL, and
245KKRQLMELAI,a s
well as a single DEF domain motif,
151FNF. All four motifs are
fully conserved throughout Drosophila species, and partially
conserved in other STAR proteins (Figure 1C). The presence of
these domains, together with the occurrence of potential
phosphorylation sites, led us to test the possibility that HOW is
phosphorylated by MAPK/ERK.
HOW is phosphorylated by MAPK/ERK in vitro
To start investigating phosphorylation of HOW by MAPK/
ERK, we generated a HOW construct in which the putative
phosphoacceptor sites T59 and T64 were mutated to Alanine
(HOW
TTAA), rendering it non-phosphorylatable.
Next, we tested whether MAPK/ERK could phosphorylate
HOW in vitro. Briefly, HOW(L)
WT and HOW(L)
TTAA were
transcribed and translated in vitro in the presence of S
35-
Methionine, incubated with recombinant activated ERK2, and
run on an SDS gel. Incubation of in vitro translated Yan, an
established MAPK substrate protein [38] with active Erk2 resulted
in a protein mobility shift on SDS Page as compared to the
unphosphorylated protein (Figure 2A, lanes 1–4). Importantly,
HOW(L)
WT but not HOW(L)
TTAA also displayed a MAPK-
dependent mobility shift (lane 5,7), indicating that MAPK
phosphorylates HOW and that the phosphorylation event occurs
on the predicted residues (Figure 2A, arrow). However, under
these conditions, HOW underwent only partial phosphorylation,
as a relatively small fraction of HOW was shifted (see below,
Figure 3).
HOW is phosphorylated in Drosophila S2R+ cells on
MAPK/ERK consensus sites
We next tested whether HOW is phosphorylated on its MAPK/
ERK consensus sites using Drosophila S2R+ cells. HOW(L)
WT and
HOW(L)
TTAA were expressed in these cells, precipitated with an
anti-HOW antibody, and subjected to Western blot analysis using
an anti-phospho-Thr-Pro (anti-pTP) antibody (Figure 2B).
HOW(L)
WT protein reacted with the anti-pTP antibody, whereas
the HOW(L)
TTAA form did not. This indicated that in unstimu-
lated cells HOW is phosphorylated at least on one TP site.
We have also examined the potential phosphorylation of a
shorter HOW isoform, HOW(S), which differs from HOW(L) only
at the C terminus [13,39]. Interestingly, although HOW(S)
WT
possesses all of the sites predicted to be phosphorylated by, and to
bind MAPK, it did not react with the anti-pTP antibody when
Author Summary
Somatic muscles are huge cells that feature highly
organized sarcomeric architecture, whose formation and
maintenance are not fully understood. Multiple signals
play a role in these cells, including the highly conserved
MAPK/ERK pathway, which often serves as a cue for
cellular proliferation or differentiation. In this study, we
reveal a role for MAPK/ERK signaling in the regulation of
multiple muscle genes at the level of mRNA, through the
control of the activity of the Drosophila RNA–binding
protein Held Out wings (HOW). Specifically, we show that
HOW undergoes phosphorylation by MAPK/ERK, which
increases its ability to form dimers and enhances its RNA–
binding capacity. We further demonstrate that HOW is
phosphorylated in embryonic and larval muscles by MAPK
in vivo and that this event is important for its ability to
regulate the levels of a giant sarcomeric gene homologous
to vertebrate titin, thus contributing to the maintenance of
muscle sarcomeric architecture. Importantly, HOW is a
close homolog of mammalian Quaking, an essential
protein in embryonic development and nervous system
myelination, a reduction of which is correlated with
Schizophrenia. Thus, our results raise the possibility that
MAPK/ERK phosphorylation similarly regulates RNA pro-
files in other tissues controlled by proteins of the
conserved Quaking family.
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PLoS Genetics | www.plosgenetics.org 2 March 2012 | Volume 8 | Issue 3 | e1002632Figure 1. HOW possesses conserved MAPK/ERK consensus phospho-acceptor sites and docking domains. A. A scheme of HOW(L)
protein domains. The locations of the TP sites at positions 59 and 64, the Glutamic acid at position 106 required for homodimerization, and the four
potential MAPK/ERK docking sites are indicated. The STAR/GSG domain is indicated by colored squares: The QUA1 domain (light blue), the maxi-KH
domain (yellow), and the QUA2 domain (green). Also indicated is the Tyrosine rich area in the C-terminus (pink). B. Alignment of HOW(L) amino acid
sequences from 12 Drosophila species. While T64 is conserved throughout all the species, T59 is only conserved in five of them (conserved residues
are demarcated by black frames). E106 is also fully conserved, as are the putative docking sites (not shown). C. Alignment of the HOW(L) protein with
the mammalian proteins QKI-5 and Sam68, and the nematode homologs, GLD-1 and ASD-2. The Qua1 domain is underlined in light blue, the maxi-KH
domain in yellow, and the Qua2 in green. Note the conserved TP sites, E106 and various docking sites, demarcated by frames. Both the DEF domain
and the second D-domain (at a.a. 121) are conserved in the mammalian proteins QKI and Sam68, whereas the first (at a.a. 85) and third (at a.a. 245) D-
domains are conserved in C. elegans proteins (the latter is also conserved in QKI).
doi:10.1371/journal.pgen.1002632.g001
Phosphorylation of the RBP HOW by MAPK/ERK
PLoS Genetics | www.plosgenetics.org 3 March 2012 | Volume 8 | Issue 3 | e1002632Figure 2. HOW(L) is phosphorylated in vitro and in S2R+ cells by MAPK/ERK on one or more TP sites. A. ERK2 phosphorylates HOW in
vitro. HOW(L)
WT and HOW(L)
TTAA (phospho mutant) constructs were in vitro translated (using S
35 labeling) and incubated with activated ERK2. The
reaction was resolved on an SDS gel. The left part of the panel (lanes 1–4) shows phosphorylation of the Yan (Aop) protein as a control. HOW(L)
WT
protein, but not the HOW(L)
TTAA mutant (lanes 7–8) exhibits a molecular weight shift of a fraction of the protein when incubated with the kinase (lane
5) relative to HOW without the kinase (lane 6). B. HOW(L), but not HOW(S), is phosphorylated in S2R+ cells. HOW proteins were immunoprecipitated
using an anti-HOW antibody and reacted with anti-pTP (top panel) and anti-HOW (middle panel) antibodies. HOW proteins in the crude extract are
shown in the bottom panel. From the left: HOW(S)
WT, HOW(L)
WT and HOW(L)
TTAA. C. Treatment with the MAPKK/MEK inhibitor U0126 decreases HOW
phosphorylation. HOW proteins were immunoprecipitated with an anti-HOW antibody from cells transfected with how(l)
WT treated (or not) with
U0126, or with how(l)
TTAA and reacted with anti-pTP antibody (top panel) or with anti-HOW antibody (2
nd from the top). The crude extract was
reacted with anti-pERK antibody (2
nd from the bottom), to confirm the extent of U0126 inhibition, and anti-Actin (bottom panel) as a loading control.
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from the distinct subcellular localization of the different HOW
isoforms; while HOW(L) is nuclear and is thus probably more
accessible to active MAPK/ERK, HOW(S) is mostly expressed
in the cytoplasm. We therefore limited our analysis to the
phosphorylation of HOW(L).
MAPK/ERK is phosphorylating HOW in S2R+ cells
We further confirmed the identity of the kinase phosphorylating
HOW in S2R+ cells by employing the specific MAPKK/MEK
inhibitor, U0126 [40] (Figure 2C). Treatment of the cells with
U0126 led to a significant decrease in pERK levels (compare the
left and middle lanes in Figure 2C). Notably, in the treated cells a
C9. Quantification of the reduction of phosphorylation following treatment with U0126. For each sample, the ratio between the pTP band
measurement and the total HOW band was calculated, and normalized to the HOW(L)
WT (non-treated sample) ratio. Results shown are the average of
three experiments; error bars indicate SEM. Following U0126 treatment, HOW phosphorylation was reduced to 0.4760.07 relative to non-treated cells
(P=0.0021, unpaired t-test, n=3). D. Same as in C, except cells were treated with TPA/PMA. A representative experiment is presented. D9.
Quantification of three TPA treatment experiments, in which HOW phosphorylation was increased by 1.2860.06 (P=0.0076, unpaired t-test, n=3).
doi:10.1371/journal.pgen.1002632.g002
Figure 3. HOW(L) phosphorylation correlates with its homo-dimerization. A. Phospho-mutant HOW(L)
TTAA oligomerizes to a lesser extent
than HOW(L)
WT. S2R+ cells were co-transfected with expression vectors for the following: gfp- how(l)
WT and how(l)
WT-HA (1) gfp- how(l)
TTAA with
how(l)
TTAA-HA (2); gfp-how(l)
EG with how(l)
EG-HA (3); or gfp with how(l)
WT-HA (4) as a control. IP was carried out using anti-GFP antibody and Western
blotting was performed with anti-HOW. Crude lysate was reacted with anti-HOW (2
nd panel from the top), anti-GFP (to visualize GFP-HOW (lanes 1–3)
and the GFP control (lane 4)), as well as with anti-Actin. A9. Quantification of lanes 1–3 from three experiments as described in A. For each sample, the
ratio between the Co-immunoprecipitated HA protein and its total crude level was normalized to the amount of the GFP protein that pulled it down.
HOW
TTAA (2) exhibited partial dimerization (0.5660.14, P=0.039 unpaired t-test, n=3). The HOW
EG (3) is almost completely non-dimerized
(0.1360.04, P,0.0001, unpaired t-test, n=3). B. HOW(L) protein that is unable to homo-dimerize undergoes significantly less phosphorylation. S2R+
cells were transfected with either how(l)
WT, how(l)
TTAA or the how(l)
EG mutant construct. Proteins were immunoprecipitated using anti-HOW antibody.
The amount of lysate used for the IP of the HOW(L)
EG protein was doubled, in order to obtain a comparable amount of immunoprecipitated HOW
protein (since it does not dimerize, less protein precipitates). B9. Quantification of two of several experiments in which the total levels of the different
proteins were comparable. For each sample, a ratio between the pTP band measurement and the total HOW band was calculated, and normalized to
the HOW(L)
WT ratio. Error bars indicate SEM (HOW(L)
EG 0.1260.10).
doi:10.1371/journal.pgen.1002632.g003
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immunoprecipitated HOW detected by anti-pTP antibody (top
panel) in comparison to non-treated cells (phosphorylation was
reduced to 0.4760.07 fold of control, n=3, Figure 2C9). This
result indicates that HOW phosphorylation is dependent on
MAPKK/MEK. Interestingly, the phosphorylation of HOW on
the TP sites was not completely eliminated, as expected from the
effective reduction in pERK levels, suggesting that another kinase
might also be involved in the phosphorylation of at least one of the
TP sites.
In a complementary approach, we stimulated MAPK/ERK
signaling using Phorbol 12-Myristate 13-Acetate (TPA/PMA).
This compound is an activator of protein kinase C [41], which in
turn leads to activation of MAPK/ERK [42]. Treatment with
TPA increased HOW phosphorylation, as indicated by stronger
reaction with the pTP antibody (Figure 2D, quantification of 3
experiments is shown in Figure 2D9).
Taken together, these experiments demonstrate that HOW is
phosphorylated by MAPK/ERK in Drosophila S2R+ cells.
MAPK/ERK-dependent phosphorylation stabilizes HOW
dimers
What could be the reason for the partial phosphorylation of in
vitro translated HOW by activated ERK (Figure 2A)? We
considered the possibility that the incomplete phosphorylation is
due to a limited degree of HOW dimerization that occurred under
our experimental conditions.
Accordingly, we examined whether MAPK/ERK phosphory-
lation was related to the degree of HOW dimerization by
performing dimerization experiments with HOW
WT and HOW
T-
TAA. Both HOW variants were fused to GFP and expressed in
S2R+ cells together with either HA-tagged HOW
WT or
HOW
TTAA, respectively. We immunoprecipitated the GFP-
HOW(L) protein using an anti-GFP antibody, and tested, using
anti-HOW antibody, the co-precipitation of HOW(L)-HA
(Figure 3A). We differentiated between GFP-HOW, HOW-HA
and the endogenous HOW by virtue of their different molecular
weights. Indeed, HOW
WT-HA readily co-immunoprecipitated
with GFP
WT-HOW (Figure 3A, lane1), indicating the two proteins
oligomerized, presumably as dimers. A negative control protein
(eGFP) did not precipitate HOW(L)-HA, demonstrating the
specificity of the interaction (Figure 3A, lane 4). Interestingly,
the non-phosphorylatable HOW
TTAA co-immunoprecipitated less
efficiently (lane 2). Quantification of the experiments, while
normalizing the co-precipitated HOW-HA levels to its levels in
the crude extract as well as to the immunoprecipitated HOW-
GFP, showed that co-precipitation of the phospho-mutant HOW
was reduced by about 40% compared to that of HOW
WT
(Figure 3A9). In addition, we attempted to examine the effect of
enhanced phosphorylation on HOW dimerization, using a
putative phospho-mimicking mutant variant, in which the two
Thr residues were replaced by Aspartic acid (HOW(L)
TTDD).
However, this mutation did not appear to mimic phosphorylated
HOW, in this as well as in other assays (data not shown). As a
control for the dimerization assay, we mutated HOW on a
Glutamic acid residue, changing it to Glycine (E106G, HOW
EG)
and similarly tagged it with HA or GFP. This residue was
previously shown to be essential for QKI [23] and GLD-1
dimerization [24]. As expected, the amount of co-precipitated
HOW
EG-HA was reduced to about 10% of wild-type levels
(Figure 3A lane 3 and Figure 3A9), confirming the reliability of our
dimerization assay. Strikingly, testing the phosphorylation state of
HOW dimerization mutant HOW
EG using anti-pTP antibody
revealed that this HOW mutant essentially does not undergo
phosphorylation by MAPK/ERK (Figure 3B lane 3, 3B9).
Collectively, the above experiments strongly suggest that
MAPK-dependent phosphorylation occurs only on HOW dimers,
although we cannot exclude a possible change of conformation in
the monomeric structure of HOW
EG [24]. Our results also further
support the idea that phosphorylation stabilizes HOW dimeriza-
tion since the extent of dimer formation of HOW
TTAA is
significantly reduced.
Phosphorylation of HOW strengthens its binding to RNA
To address whether the phosphorylation of HOW influences its
ability to bind RNA, we performed an RNA binding assay. In this
experiment, wild-type HA-tagged HOW(L) was affinity purified
from S2R+ cells that were either grown in normal medium (in
which HOW is phosphorylated, see Figure 2C) or in medium
containing the MEK inhibitor U0126 (in which HOW phosphor-
ylation is reduced, shown in Figure 2C). The RNA-binding activity
of purified HOW-HA was then tested using biotin-labeled RNA
oligomers that either contained or did not contain the HOW
response element (HRE) [43]. A significant reduction of about
70% in the binding of HOW to the RNA was detected following
treatment with the MEK inhibitor U0126 (Figure 4A, left lane). In
addition, HOW(L)
EG, the mutant form that does not dimerize,
exhibited an extremely low RNA binding activity, supporting a
role for the dimerization of HOW in RNA binding (Figure 4A,
right lane). Notably, the non-phosphorylatable HOW(L)
TTAA only
showed slightly reduced binding (Figure 4A, second lane from the
right, about 20% reduction), possibly due to its ability to dimerize
with endogenous, phosphorylated HOW protein (contrary to the
U0126-treated cells, where all HOW proteins are less phosphor-
ylated). This experiment demonstrates that ERK-dependent
phosphorylation of HOW enhances not only its homodimerization
but also its RNA binding activity, suggesting that both functions
are linked.
Thr phosphorylation does not alter the subcellular
localization of HOW
Phosphorylation alters the subcellular localization of Sam68
[4,32], raising the possibility that, via this mode of regulation,
MAPK impinges on HOW’s ability to bind and regulate its RNA
targets. To address this issue, we transfected S2R+ cells with
HOW
WT or HOW
TTAA tagged with HA, and stained with an
anti-HA antibody. We did not detect any alteration in the
subcellular localization of HOW(L)
TTAA relative to HOW(L)
WT
(Figure 4B–4C9). Thus, HOW Thr phosphorylation does not alter
its subcellular localization.
HOW is phosphorylated on T64 in the embryo in vivo
To follow the pattern of HOW phosphorylation in vivo,w e
generated a polyclonal antibody designed to specifically recognize
HOW only when it is phosphorylated on the more conserved Thr
residue, T64 (we refer to the antibody as anti-pHOW (pT64) (see
Materials and Methods)). We first confirmed the specificity of the
antibody by transfecting S2R+ cells with how(l)
WT, how(l)
TTAA, and
by treating a sample of the HOW(L)
WT expressing cells with the
MAPKK/MEK inhibitor U0126. We performed immunoprecip-
itation (IP) with an anti-HOW antibody and used anti-pHOW
(pT64) antibodies in Western blot analysis (Figure 5A). The
antibody reacted with the immunoprecipitated HOW(L)
WT (lane
2) but not with HOW(L)
TTAA (lane 4) nor with non-transfected
cells (lane 1). In the sample treated with U0126 (lane 3), the
reactivity of the antibody was significantly reduced, suggesting the
Phosphorylation of the RBP HOW by MAPK/ERK
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T64.
We used the anti-pHOW (pT64) antibody to identify tissues in
which HOW is phosphorylated (Figure 5C). To this end, we
stained wild-type Drosophila embryos, employing how mutant
(how
stru2/2) embryos, in which zygotic HOW is not produced, as
a control for antibody specificity. The embryos were also co-
stained with a general anti-HOW antibody. Specific anti-pHOW
staining was detected in the nuclei of somatic muscles (Figure 5C,
open arrow) as well as in the heart cardioblasts (Figure 5C, white
arrow). This staining co-localized with anti-HOW staining
(Figure 5D, corresponding arrows) and was reduced to back-
ground levels in how
stru mutants (Figure 5E, 5F). Importantly,
phosphorylated HOW was confined to the nuclei of the somatic
muscles that were marked with muscle-specific expression of CD8-
GFP (which localizes to the cell membrane but often concentrates
in the ER surrounding the nuclei), as shown in Figure 5G–5I. This
result indicates that HOW is phosphorylated on T64 in muscle
nuclei.
Intriguingly, the anti-pHOW (pT64) antibody did not label
tendon cells, which exhibited a strong anti-HOW staining
(Figure 5C, 5D, open arrowheads), further validating the
specificity of our antibody. The lack of pHOW staining is not
simply due to low levels of MAPK in these cells, since previous
analysis demonstrated high level of phospho-ERK in tendon cells
at this stage [44]. We therefore hypothesized that the HOW(L)
isoform found to be specifically phosphorylated by MAPK/ERK
(Figure 2) is not expressed at high levels in tendon cells at this
developmental stage and that the anti-HOW staining is mainly
detecting HOW(S), which does not undergo phosphorylation in
S2R+ cells (Figure 2B). To directly address this possibility, we
generated transgenic flies expressing HA-tagged versions of
HOW(L)
WT or HOW(L)
TTAA under UAS-GAL4 binding se-
quences. The expression of HOW(L)
WT or HOW(L)
TTAA was
driven in embryonic tendon cells by the tendon-specific driver, sr-
GAL4, and the embryos were stained for pHOW (Figure 5J–5M)
Whereas over expression of HOW(L)
WT in tendon cells led to
positive nuclear staining with the anti-pHOW antibody (Figure 5J,
5K arrows), overexpression of HOW(L)
TTAA did not result in such
a staining (Figure 5L, 5M arrows). This experiment shows that the
kinase required for HOW phosphorylation on T64 is activated in
tendon cells, and that the lack of reactivity of the antibody in wild-
type tendon cells at late embryonic stages is due to low levels of
HOW(L) in this tissue. This is also consistent with the cytoplasmic
HOW staining characteristic of the HOW(S) isoform present at
stage 16 embryos [39].
Based on these results, we conclude that HOW(L) is
phosphorylated on T64 in the nuclei of somatic muscles and
heart cardioblasts. To further verify that HOW undergoes Thr
phosphorylation in embryonic somatic muscles, we also expressed
HA–tagged HOW(L)
WT or HOW(L)
TTAA in muscles using the
mef2-GAL4 driver. The HOW variants were subsequently
immunoprecipitated using anti-HA conjugated beads and reacted
with anti-pHOW (pT64) antibodies on Western blots (Figure 5B,
lane 2). Only HOW(L)
WT but not HOW(L)
TTAA (lane 3), was
detectable by the anti-pHOW antibody. In addition, an anti-
HOW antibody identified an additional upper band that might
represent phosphorylated HOW (lane 2). To conclude, these
findings strongly indicate that HOW(L) undergoes phosphoryla-
tion on T64 in embryonic somatic and cardiac muscles and that
phosphorylated HOW in muscles is localized specifically to the
nucleus.
HOW(L) downregulates Sallimus in muscles in a
phosphorylation-dependent manner
To further characterize the physiological significance of
MAPK/ERK-dependent phosphorylation of HOW, we focused
on somatic muscles, a tissue in which a high degree of HOW
phosphorylation was detected. Recently, HOW was shown to be
essential for muscle sarcomerization [45]. Specifically, in larvae
where how was knocked down (using how RNAi expressed
specifically in muscles), the sarcomeric organization is aberrant.
In these larvae, the Z discs appear discontinuous and spotty, a
phenotype similar to that caused by the knock down of several
genes encoding sarcomeric proteins [45]. To address the possibility
that this phenotypic resemblance is a result of regulation of one or
Figure 4. HOW phosphorylation strengthens its affinity to RNA, while not affecting its subcellular localization. A. In vitro RNA-protein
binding assay. HA tagged HOW(L)
WT, HOW(L)
TTAA or HOW(L)
EG constructs were purified from S2R+ cells by immunoprecipitation of the HA tag,
followed by elution with free HA peptide. HOW(L)
WT transfected cells were either treated with U0126 or not treated. Equal volumes of purified
proteins were incubated with biotin labeled 12 nt oligomers that either bind HOW (top panel) or do not bind HOW (middle panel). The complexes
were incubated with avidin beads, eluted by boiling in sample buffer and reacted with anti HOW in a Western blot. The amounts of HOW protein
used for each reaction were comparable (bottom panel). B–C9. Localization of HOW(L) was not altered due to the mutations in the Thr residues. Cells
expressing either HOW(L)
WT (B,B9) or HOW(L)
TTAA (C,C9) were stained for HOW (red, B–C). Merge images (B9–C9) also present GFP (green, marks
transfected cells) and Lamin (blue).
doi:10.1371/journal.pgen.1002632.g004
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PLoS Genetics | www.plosgenetics.org 7 March 2012 | Volume 8 | Issue 3 | e1002632Figure 5. Phosphorylated HOW is detected in the nuclei of somatic muscles and cardioblasts. A. Anti-pHOW (pT64) antibody reacts with
HOW, in a phosphorylation-dependent manner. HOW protein was immunoprecipitated with an anti-HOW antibody from S2R+ cells transfected with
either HOW(L)
WT, treated (or not) with U0126 (lanes 3, 2 respectively), with HOW(L)
TTAA (lane 4), or no HOW (lane 1). The IP was reacted with anti-
pHOW (pT64) antibody (top) or with anti-HOW antibody (middle). The crude extract was reacted with anti-pERK antibody (bottom), confirming U0126
inhibition. Note specific reactivity of the anti-pHOW antibody. B. Anti-pHOW (pT64) antibody reacts with HOW protein overexpressed in embryonic
muscles and heart. Transgenic UAS-HOW(L)
WT (lane 2) and UAS-HOW(L)
TTAA (lane 3) flies or wild-type controls (lane 1) were crossed to the mef2-GAL4
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sarcomeric proteins in 3
rd instar larvae, in which we reduced
HOW levels using RNAi mediated knock-down in muscles. To
enhance the effect of how down-regulation, the larvae used were
also heterozygous for how
stru.
Under these conditions, we observed an increase in the
500 kDa isoform of Sls, a giant protein that serves as a scaffold in
the sarcomere, linking the Z-discs to the thick filaments [33]
(Figure 6A). In contrast, the levels of MSP-300 (isoform
800 kDa), a Z-disc protein [46,47], were decreased (Figure 6A).
This suggests that in wild-type larval muscles, Sls is down-
regulated by HOW, while MSP-300 is elevated. Although these
results do not distinguish between direct and indirect effects,
nonetheless, we used the levels of these two proteins in muscles as
readout of the activity of phosphorylated (HOW
WT)v e r s u sn o n -
phosphorylated HOW (HOW
TTAA) in this developmental
process.
Accordingly, we expressed comparable amounts of either
HOW
WT or HOW
TTAA in muscles (using the mef2-GAL4 driver)
and followed the expression of Sls and MSP-300 by fluorescent
labeling (Figure 6B–6D) or by Western blot analysis (Figure 6E) in
3
rd instar larvae. As expected, over-expression of HOW(L)
WT
resulted in reduced levels of Sls (Figure 6C). This was confirmed by
measuring the immunofluorescence intensity of Sls in Z-discs (see
legend to Figure 6). Importantly, overexpression of HOW(L)
TTAA
exhibited a significantly milder effect on Sls levels (Figure 6D). In
contrast, over-expression of either HOW
WT or HOW
TTAA
resulted in a similar aberrant distribution of MSP-300
(Figure 6C9,6 D 9).
We also quantified the changes in protein levels by employing
Western blot analysis of extracts from the body walls of several
larvae, expressing driver alone (mef2-GAL4), or together with
HOW
WT or HOW
TTAA (Figure 6E). Consistent with the
immunofluorescent staining, the anti-Sls antibody reacted with a
major band of 500 kDa that was downregulated following
HOW(L)
WT overexpression. A much milder effect was observed
following HOW(L)
TTAA overexpression (Figure 6E, upper band).
Myosin Heavy Chain (MHC) [48,49] was reduced following
expression of both HOW
WT and HOW
TTAA (Figure 6E second
band from top). Of the three distinct bands representing MSP-300
(900 kDa, 800 kDa, 300 kDa), the 900 kDa and the 300 kDa
bands were elevated, whereas that of 800 kDa was unaffected
following HOW
WT overexpression. No significant differences were
found between the effect of HOW
WT and HOW
TTAA on all three
bands. The levels of two additional muscle proteins, MLP84B [46]
and Actin remained unchanged in these genetic backgrounds.
To conclude, the down-regulation of the newly-identified HOW
target, Sls, is dependent on the phosphorylation state of HOW,
whereas MSP-300 and MHC are regulated by HOW in a
phosphorylation-independent manner. This discrepancy may be
due to differential activities of HOW (e.g. regulation at the level of
RNA degradation versus alternative splicing).
Given that HOW is an RBP, we next sought to determine
whether HOW controls sls RNA levels, and if so, whether
phosphorylation is important for this type of regulation. To this
end, we purified total RNA from the body walls of single 3
rd instar
larvae and performed real-time PCR to quantify the levels of the
sls and how transcripts (rp49 RNA served as control) using the
SYBR green method. We compared larvae from a wild-type
background (w
2), to larvae heterozygous for how
stru which
expressed how RNAi in muscles, and to larvae over-expressing
either HOW(L)
WT or HOW(L)
TTAA in muscles. In larvae
expressing lower levels of how (Figure 6F9, second left bar, RNAi),
sls mRNA was upregulated (Figure 6F). Importantly, HOW(L)
WT
was more efficient in the down-regulation of sls RNA relative to
HOW(L)
TTAA (Figure 6F right bars). Although this result was not
statistically significant, the trend seen at the level of RNA is
consistent with the results obtained in the protein analysis. Thus,
our data demonstrate that HOW(L) has a role in the down-
regulation of sls mRNA and protein levels in muscles, and that this
process is dependent on HOW phosphorylation.
Downregulation of MAPK signaling in larval muscles
results in diminished phosphorylation of HOW and
elevation of Sallimus protein levels
We next examined whether HOW phosphorylation in muscles,
and its resulting elevated activity in the regulation of Sls levels
(Figure 6), are indeed dependent on MAPK signaling. To test this
idea, we expressed RNAi for the Drosophila MAPK gene rolled in
larval muscles under mef2-GAL4 regulation, immunoprecipitated
HOW from protein extracts of these larvae and examined HOW
phosphorylation using Western blot analysis with an anti-pTP
antibody (Figure 7A). Importantly, in the larvae where rolled was
down regulated (note the reduction in the levels of pERK in
Figure 7B), we observed diminished phosphorylation of HOW,
compared to wild-type larvae (Figure 7A). The phosphorylation of
HOW in wild-type larvae was present in a band corresponding to
the HOW(L) protein. Thus, phosphorylation of HOW(L) in larval
muscles in vivo is dependent on MAPK signaling, as in S2R+ cells
and in an in vitro kinase assay (Figure 2).
Since rolled down regulation resulted in decreased HOW(L)
phosphorylation, we hypothesized that HOW(L) activity will be
lowered in these larvae, resulting in elevated levels of Sls. Indeed,
using a Western blot analysis (Figure 7B) we find that in larvae
expressing rolled RNAi under mef2-GAL4, Sls levels are signifi-
cantly elevated. The increase in Sls levels is specific, as only a mild
increase is observed in MHC levels, while MSP and a-Actinin
levels are unaffected (Figure 7B). The marked elevation of Sls
levels following reduction of rolled in the larval muscles is also
readily detectable in individual muscles (Figure 7C, 7F), while
MSP-300 levels remain constant (Figure 7D, 7G, merge in
Figure 7E, 7H). Thus, we conclude that in wild-type larval
muscles, MAPK signaling is required for HOW(L) phosphoryla-
tion and reduction of Sls protein levels.
driver line. Embryos were collected, and protein extracts were subjected to IP with an anti-HA antibody followed by Western with anti-pHOW (pT64)
antibody (top), and anti-HOW antibody (2
nd from top). Crude extracts were reacted with anti-HOW (2
nd from bottom), and anti-Actin (bottom) as a
loading control. C-F. Drosophila embryos stained with anti-pHOW (pT64) exhibit specific staining in somatic muscles and heart cardioblasts. Stage 16
WT (C,D) and how
stru mutant (E,F) embryos were stained with anti-pHOW (pT64) (red, C–F) and anti-HOW (green in merge D,F). Embryos are oriented
dorsal to the top and anterior to the left. (C,D) Note the staining in muscles (hollow arrow), heart cardioblasts (white arrow) and the lack of pHOW
staining in the muscle attachment sites (arrowhead). (E,F) Weak staining in cardioblasts in how
stru2/2 mutants. G–I. Drosophila embryos expressing
CD8-GFP, which localizes at the plasma membrane, but also often concentrates in the ER surrounding the nuclei, in muscles under mef2-GAL4, were
stained with anti-pHOW (red, G) shown merged with GFP (green, H) and with HOW (blue, I). J–M. HOW(L) overexpressed in embryonic tendon cells
reacts with the anti-pHOW (pT64) antibody. Embryos expressing UAS-HOW(L)
WT-HA (J,K) or UAS-HOW(L)
TTAA–HA (L,M) in the tendon cells under sr–
GAL4 were stained with anti-pHOW (pT64) (red, J–M) and anti-HA (green, K, M, merged with the anti-pHOW staining). Arrows mark tendon cells
reactive with anti-pHOW upon expression of HOW(L)
WT (J,K), or non-reactive upon expression of the phospho-mutant (L,M).
doi:10.1371/journal.pgen.1002632.g005
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PLoS Genetics | www.plosgenetics.org 9 March 2012 | Volume 8 | Issue 3 | e1002632Figure 6. HOW regulates the levels of Sls RNA and protein in a phosphorylation-dependent manner. A. Sls and MSP-300 are directly or
indirectly regulated by HOW. Extracts from larvae in which HOW was down-regulated by expressing how RNAi (aimed against all HOW isoforms)
under mef2-GAL4, on the background of how
stru heterozygotes, were reacted with anti-Sls, MSP-300, and HOW antibodies and compared to larvae
heterozygotes for mef2-GAL4 in Western blot analysis. Down-regulation of HOW (lower panel) led to upregulation of Sls (upper panel) and down-
regulation of MSP-300 (middle panel). B–D. Overexpression of HOW leads to reduction of Sls protein levels, in a phosphorylation-dependent manner.
Body wall muscles from 3rd instar larvae expressing mef2-GAL4 alone (B,B9,B0), UAS-HOW(L)
WT-HA, or UAS-HOW(L)
TTAA-HA driven by the mef2-GAL4
driver (C,C9,C0 and D,D9,D0, respectively) were stained with anti-Sls (B,C,D - red), anti-MSP-300 (B9,C9,D9- blue) and anti-HA (B0,C0,D0 - green, shown
within merge). Quantification of at least three larvae from each genotype showed that HOW(L)
WT over-expression reduced Sls intensity to 0.7160.05
of the intensity of the mef2 -GAL4 heterozygotes, while the HOW(L)
TTAA protein only reduced it to 0.8360.03 of control (P=0.049, ANOVA test). E.
Overexpression of HOW(L) in larval muscles alters the levels of multiple muscle proteins, of which only Sls is affected in a HOW phosphorylation-
dependent manner. Protein extracts from 2
nd instar larvae expressing mef2-GAL4 alone (middle), or either HOW(L)
WT (left) or HOW(L)
TTAA (right)
driven by mef2-GAL4 were analyzed by Western blotting with the following antibodies (from top to bottom): anti-Sls, anti-MHC, anti-MSP300 (reacts
with three different isoforms), anti-MLP84B, anti-Actin, and anti-HOW. Note the comparable levels of HOW(L)
WT and HOW(L)
TTAA expression, and the
relatively mild reduction in Sls when HOW(L)
TTAA is overexpressed. F–F9. HOW regulates Sls at the RNA level. RNA was extracted from single 3
rd instar
larvae, and real-time PCR was performed with sls primers (F) and how primers (F9), both normalized to rp49 as a control. From left to right: mef2-GAL4
heterozygotes (w2), how
stru+/2, mef2.how RNAi (RNAi), and mef2-GAL4 driving either HOW(L)
WT or HOW(L)
TTAA. Error bars indicate SEM. While
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STAR proteins regulate tissue differentiation in a wide range of
speciesincludingnematodes[50],flies[17],Zebrafish[8],mice,and
humans [51]. They function by controlling diverse posttranscrip-
tional events, often forming specific protein-RNA complexes
mediated by 39UTR sequences of their target mRNAs, or with
alternatively spliced introns [2]. In this study we reveal a molecular
mechanism regulating the activity of the STAR protein HOW. Our
findings demonstrate that HOW is phosphorylated on Thr residues
embedded within conserved MAPK consensus sequences, both in
cultured cells as well as in muscle cells and heart cardioblasts
(Figure 2, 5), and that this phosphorylation is executed by MAPK/
ERK(Figure 2, 7).Significantly,ourresultsprovide novel molecular
insights to the importance of this phosphorylation, demonstrating
that phosphorylation stabilizes HOW dimer formation (Figure 3).
Moreover, because phosphorylation presumably occurs only on
dimers, and phospho-dimers are more stable, we propose that a
feed-forward loop ensures that a large fraction of HOW dimers are
formedfollowinga shorttemporal burstofMAPK/ERK activation.
Importantly, since STAR proteins are evolutionarily conserved, the
novel mode of regulation that we have uncovered might have
important implications for other members of the QKI sub-family.
Two of the four potential MAPK/ERK docking sites reside
within the HOW QUA1 domain. The close proximity between
these sites, the MAPK/ERK phosphorylation sites, and the E106
residue critical for dimerization ([23,24], Figure 3), all of which are
highly evolutionarily conserved (Figure 1), is consistent with local
conformational changes in the QUA1 domain induced by
phosphorylation, which further lead to dimer formation and
stabilization. HOW dimerization might be essential for a number
of its characteristics; first, it enables binding to several HREs
present on a single target RNA, leading to an overall higher
affinity of HOW to its target RNA. For example, the 39UTR of
the HOW target stripe contains three consecutive HREs and a half
site that resides between the first and second HREs. We have
previously shown that a higher affinity of HOW is observed when
multiple HREs are clustered together [43]. HOW dimerization
and binding to two sites may also contribute to the formation of a
secondary RNA structure, thus facilitating RNA processing.
Interestingly, HOW dimerization apparently enhances its RNA
binding ability even to a single binding site (Figure 4A).
Additionally, HOW dimerization might also potentiate the
recruitment of other proteins/enzymes to the vicinity of the
targeted mRNA. This may occur either if one subunit associates
with the target RNA, and the other with a specific enzyme that
induces modification/degradation of the target RNA, or if the
formation of HOW dimers enables recruitment of proteins that
would not associate with its monomeric form. A similar
mechanism has been proposed to take place when GLD-1 dimers
associate with their RNA target(s) close to the polyadenylation site,
possibly recruiting an E3 ubiquitin ligase complex to this site.
Ubiquitination of the polyadenylation complex would subsequent-
ly lead to shortening of the poly-A tail [24]. A mechanism for
HOW activity that includes protein interactions with binding
partners has yet to be described, but such an interaction is highly
likely, since HOW does not contain any recognizable catalytic
domains that could independently lead to mRNA degradation.
We show that a HOW mutant unable to form dimers exhibits a
greatly diminished RNA binding capacity (Figure 4A, HOW
EG
mutant). This is also in line with our findings that HOW binding
to RNA is significantly reduced when it is hypophosphorylated,
and that phosphorylated HOW has a higher tendency to form
dimers. We conclude that dimeric HOW binds RNA with higher
affinity than monomeric HOW. This conclusion is in line with the
observations that GLD-1 lacking its QUA1 domain has a lower
affinity to RNA [26], and possibly applies to other STAR proteins.
To our knowledge, this is the first example of a positive effect of
phosphorylation of a STAR protein on its RNA binding capacity.
Phosphorylation of Sam68 by MAPK/ERK was demonstrated to
have a subtle negative influence on its RNA binding [32,52], while
Tyrosine phosphorylation was shown to more severely impair
RNA binding of both QKI [29] and Sam68 [53]. As the Tyrosine
residues in HOW are highly conserved with those of QKI, it is
highly likely that they are also phosphorylated (Kirenberg and
Volk, unpublished data), and that this phosphorylation may have
an opposite, negative effect on the ability of HOW to bind its
targets. Hence, it is interesting to note that changes in cellular
signaling may have the capacity to fine-tune, both positively and
negatively, the ability of an RNA binding protein to bind its
targets, thus modulating the levels of a variety of mRNAs.
A requirement for HOW in developing muscles had been
demonstrated previously [45], but its target RNAs in this tissue
have not been characterized. In this study, we identify three
different muscle proteins, Sls, MSP-300 and MHC, whose levels
are altered by the expression of HOW in this developmental
setting. We still do not know whether the mRNAs of these proteins
are all directly bound by HOW, and at what level the regulation
by HOW occurs, i.e. via control of specific alternative splicing or
by regulation of overall mRNA levels. Since sls mRNA levels
respond to both HOW overexpression and knock-down, and given
that the sls transcript contains several potential binding sites for
HOW (both at the 39UTR as well as within several introns; not
shown), it likely represents a true direct RNA target of HOW.
Even though Sls is a structural protein, its fast turnover in
sarcomeres might be essential for maintenance of the sarcomeric
architecture [54]. To fulfill this requirement, its protein and RNA
half-life should be short. Thus, HOW might play an essential role
in promoting destabilization of sls mRNA to promote fast
exchange of newly formed Sls protein at the Z-disc. Indeed, in
muscles where MAPK signaling was downregulated using rolled
RNAi, a significant elevation in Sls levels is clearly evident
(Figure 7). This result is in line with tight regulation of Sls levels
occurring in wild-type larvae.
Although the precise RTK signaling pathway that regulates
HOW phosphorylation in muscles is yet to be elucidated, the
FGFR Heartless, which is expressed by muscle cells throughout
their development [55,56], is an attractive candidate. It is possible
that continuous FGFR activation in muscles promotes HOW
phosphorylation by MAPK, rendering it more active in controlling
the levels of its target mRNAs in this tissue.
In summary, in this study we have unraveled and characterized
a novel molecular mechanism at the basis of the activity of the
STAR protein, HOW. By linking its activity to MAPK/ERK-
dependent phosphorylation and regulation, we provide a mech-
anistic linkage between HOW phosphorylation, the degree of its
dimerization and its biological activity/function. We propose that
this mechanism may apply to other STAR proteins, in which the
dimerization domain and phosphorylation sites are evolutionarily
conserved.
reduction of HOW levels elevated sls (1.3860.11, P=0.039), overexpression of HOW(L)
WT reduced it more efficiently (0.5460.20, P=0.08) than
HOW(L)
TTAA (0.9260.18, P=0.78) (Student’s t-test, n=3 or 4).
doi:10.1371/journal.pgen.1002632.g006
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Expression constructs for cell lines and flies
Mutant HOW(L) constructs (
TTAA,
EG) were created by site
directed mutagenesis (Stratagene), following the manufacturer’s
protocols. pUAST-HOW(L) constructs tagged with HA or fused
with GFP were generated in the pTWH and pTGW Drosophila
Gateway vectors, respectively (T. Murphy, Carnegie Institution of
Washington) using the Gateway cloning system (Invitrogen).
Figure 7. Drosophila MAPK rolled is directing HOW phosphorylation in muscles and regulation of Sallimus levels. A. HOW was
immunoprecipitated from lysates of 3
rd instar larvae either expressing rolled RNAi in muscles under mef2-GAL4 (left) or of wild-type mef2-GAL4
heterozygotes (w2, right) and reacted with a pTP antibody to observe its phosphorylation level and with anti-HOW to compare total HOW levels. The
crude extract was reacted with anti-HOW and anti-Tubulin as a loading control, showing that the total quantity of HOW is not significantly altered by
MAPK/Rolled levels. Note the reduction in HOW phosphorylation following expression of rolled RNAi. B. Reduction in MAPK/Rolled levels elevates Sls
protein levels. Same genotypes as in A were analyzed by Western with the following antibodies (from top to bottom): anti-Sls, anti-MHC, anti-
MSP300, anti-pERK (to verify the reduction in activated MAPK in these larvae) and anti-a-Actinin as a loading control. C–H. Wild-type (C–E) and mef2-
GAL4.rolled RNAi (F–H) larvae were stained with anti-Sls antibody (red, C,F) and anti MSP-300 (blue, D,G). Merge is shown in E,H. Note the significant
elevation in Sls levels following down regulation of MAPK/Rolled levels.
doi:10.1371/journal.pgen.1002632.g007
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Fly stocks used in this study include w
2, mef2-GAL4
(Bloomington stock center), mef2-GAL4, UAS-CD8 GFP (F.
Schnorrer, Martinsried, Germany), stripe-GAL4 (G. Morata,
Madrid, Spain), how
stru [57], how RNAi line (ds-HOW) [43], rolled
RNAi (TRiP HMS00173, Bloomington stock 34855). UAS-
how(l)
WT-3HA and
TTAA-3HA were injected to flies by Genetic
Services, Sudbury, MA, USA.
Antibodies
Primary antibodies used in this study include mouse anti-
phospho-Thr-Pro (p-Thr-Pro-101) (Cell Signaling Technology),
rabbit and rat anti-HOW [39], guinea pig anti-MSP-300 [47], rat
anti-Sls (Kettin) (Klg16, MAC155, Abcam), rat anti a-Actinin
(Abcam), rabbit anti-MHC (P. Fisher, Stony Brook, NY), mouse
anti-Actin (Sigma), rabbit anti-Mlp84bB [58], mouse anti-GFP
(Roche), mouse anti-HA (Roche), chick anti-HA (Aves Labs),
mouse anti-Lamin ([59], gift from Y. Gruenbaum, Hebrew
University), mouse anti-pERK (gift from B. Shilo, Weizmann
Institute). The polyclonal anti-pHOW (pT64) antibody was raised
in rats against the phospho-peptide PQHL(p)TPQQ (generated by
Sigma), corresponding to amino acids 60–67 of HOW. Immuni-
zations were performed by the antibody unit at the Weizmann
Institute. The serum was cleaned on beads conjugated to a similar
peptide, PQHLQPQQ, in an attempt to reduce background
staining that was suspected to be due to another protein containing
this sequence. Secondary antibodies used in this study include
various Cy3, Cy2, Cy5 and HRP-conjugated antibodies (Jackson
ImmunoResearch Laboratories, USA).
Tissue culture and transfection
S2R+ cells were grown and transfected essentially as previously
described [43], except that cells were usually collected for analysis
36 hours after transfection. For inhibition of MAPK/ERK
activity, 10 mM U0126 (Sigma) in DMSO (or only DMSO for
controls) was administered with the serum-containing media,
about 18 h after the transfection. Since U0126 led to a decrease in
the efficiency of recovery from transfection, the control cells were
transfected with smaller amounts of how DNA. Phorbol 12-
Myristate 13-Acetate (TPA/PMA) (Sigma) treatment (10 mMi n
DMSO, or only DMSO for controls) was performed on starved
cells, 20 h after transfection, for 15 min.
Cell lysis
Cells were scraped off the flasks and collected in PBS, washed
twice and lysed in 1% NP40 lysis buffer (50 mM Tris pH 7.5, 1%
NP40, 100 mM NaCl, 1% Protease inhibitor cocktail (P8340,
Sigma), 0.5% Phosphatase Inhibitor Cocktail 1(P2850, Sigma),
20 mM b -glycerol phosphate).
Embryos and larvae were collected and crushed in RIPA buffer
(1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS, 0.15M
NaCl, 0.05M Tris pH 7.0, supplemented with the same
inhibitors).
Western blotting and immunoprecipitation (IP)
For IP, equal amounts of protein lysate were incubated with
protein A/G beads (SC-2003, Santa Cruz) coupled with either
rabbit anti-HOW polyclonal antibody or mouse anti-GFP mono-
clonal antibody, or agarose HA conjugated beads (A2095, Sigma)
for1–2 h at4uC.Beadswerewashedthreetimeswith the NP40 lysis
buffer, and boiled in protein sample buffer to elute the proteins.
MAPK/ERK in vitro phosphorylation assay was performed as
described [60]. High molecular weight proteins were analyzed by
SDS–PAGE using 2.5% acrylamide gels strengthened with 1.5%
agarose, essentially as in [61].
Fixation and immunostaining
Fixation and staining of embryos were done following standard
procedures. Larval Flat Preparations were performed essentially as
described [62], except the fixation was done in 4% PFA, the
primary antibody staining was carried out for 2 h and the
secondary for 1 h. Quantification of average intensity of larval
muscles images were performed using MATLAB.
S2R+ cells were seeded on Ibidi u-Slide 8 well (0.2*10
6 cells per
well), fixed with 3% PFA for 5 min, permeabilized using 3%
PFA+0.1% TritonX-100, stained with primary antibody (1:200)
for 30 min, and secondary antibody (1:400) for 30 min.
Visualization was carried out using a Zeiss LSM710 confocal
system.
RT–PCR analysis of RNA extracts
Single larvae were flipped over and their interior was cleaned,
leaving the carcass only. RNA was extracted by the Nucleospin
Purification Kit (Macherey-Nagel) according to the manufactur-
er’s instructions. Equal amounts were used as a template for cDNA
preparation using the Verso cDNA kit (Thermo Scientific). Real
time PCR was carried out using Fast SYBR Green Mastermix
(Applied Biosystems) in a StepOne plus machine (Applied
Biosystems). The following primers were used:
sls (TGCCCATGCCGAAGACA) and (TGTCTTGTTTG-
CTGTTACGTTTACAG),
rp49 (GACCATCCGCCCAGCATAC) and (CCATTTGTG-
CGACAGCTTAGC),
how (AACTTTGTCGGTCGCATTTT) and (CGTCCTCC-
TTCTTCTTGTCG).
RNA–protein binding
In vitro RNA–protein binding assay was performed essentially as
described [43], only that the proteins were not in vitro translated,
but were purified from S2R+ cells using immunoprecipitation with
HA conjugated beads, followed by elution with an HA peptide
(Sigma, I2149).
Software
Phosphorylation sites were predicted by the GPS2.1 program
[63]. Protein scheme was generated by DOG2.0 software [64].
Student’s t-tests were performed using GraphPad software.
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